Pirarubicin in advanced breast cancer: a French cooperative phase II study.

Abstract

79 patients with advanced breast cancer were given Pirarubicin 20-25 mg/m2 during 3 consecutive days every 3 or 4 weeks. 78 were evaluable for response (41 without previous chemotherapy and 37 with only one previous regimen). The overall response rate was 35% (95% CI 24-45) and the complete response rate was 8%. In previously untreated patients, the response rate reached 41.5%. The limiting toxicity was a non-cumulative granulocystopenia, sometimes severe at these high doses, with a prompt recovery. The non-haematological toxicities were mild, and included 13% with grade 3 alopecia.

• Authors: M Spielmann, P Kerbrat, T Delozier, P Fumoleau, A Monnier, B Chevallier, P Bastit, M Namer, A Cattan, P Lucas
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 26 Issue 7 Pg. 821-3 ( 1990) ISSN: 0959-8049 [Print] England
• PMID: 2145903 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Doxorubicin
• pirarubicin

Topics

• Adult
• Aged
• Agranulocytosis (chemically induced)
• Alopecia (chemically induced)
• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (drug therapy)
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Drug Evaluation
• Female
• Heart (drug effects)
• Humans
• Middle Aged